863034-64-4

Usage

Molecular structure

The compound has a pyrazole core and carboxylic acid functional group, with substituted phenyl rings.

Classification

It is a heterocyclic compound.

Potential applications

It has potential uses in pharmaceuticals and agrochemicals.

Chlorophenyl and dichlorophenyl groups

The presence of these groups indicates its potential for use as a pesticide or herbicide.

Unique structure and properties

The compound's structure and properties make it a valuable target for research and development in medicinal and agricultural chemistry.

Upstream product

• 33185-97-6 4-(4-chlorophenyl)-2-oxo-3-butenoic acid 
• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 
• 222052-48-4 sodium 4-chlorobenzylidenepyruvate 
• 13123-92-7 (2,4-dichlorophenyl)hydrazine 
• 1057395-87-5 (Z)-4-(4-chlorophenyl)-2-oxo-3-butenoic acid 
• 33185-97-6 (E)-4-(4'-chlorophenyl)-2-oxo-3-buteneoic acid 

Downstream Products

• 861151-12-4 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydro-1H-pyrazole-3-carboxamide 
• 863034-65-5 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazole-3-carboxylic acid chloride 
• 1039039-75-2 (R)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid (-)-Cinchonidine 
• 923286-80-0 (S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid (-)-Cinchonidine 

Relevant academic research and scientific papers

Substituted pyrazoline for preventing weight gain

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

Combination of substituted pyrazolines and agent for treating dyslipidemia

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one lipid lowering compound used to treat dyslipidaemia, a medicament comprising said active substance combination, a pha

A-polymorph of a substituted pyrazoline, its preparation and use as medicaments

The present invention relates to the α-Polymorph of (rac)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide, methods for its preparation, medicaments comprising this compound as well as their use for the prepara

Active substance combination for the treatment of diabetes

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation

Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: Synthesis, biological evaluation, and molecular modeling in the homology model

A number of analogues of diaryl dihydropyrazole-3-carboxamides have been synthesized. Their activities were evaluated for appetite suppression and body weight reduction in animal models. Depending on the chemical modification of the selected dihydropyrazole scaffold, the lead compounds - the bisulfate salt of (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid morpholin-4-ylamide 26 and the bisulfate salt of (-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid morpholin-4-ylamide 30-showed significant body weight reduction in vivo, which is attributed to their CB1 antagonistic activity and exhibited a favorable pharmacokinetic profile. The molecular modeling studies also showed interactions of two isomers of (±)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 9 with CB1 receptor in the homology model similar to those of N-piperidino-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (rimonabant) 1 and 4S-(-)-3-(4-chlorophenyl)-N-methyl-N′-[(4-chlorophenyl) -sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine (SLV-319) 2.

SUBSTITUTED PYRAZOLINE COMPOUNDS: METHODS FOR THEIR PREPARATION

Methods for obtaining the substituted pyrazoline compounds of general formula (Ia) as well as the intermediates of general formula (III) to this compound. Thus 5-(R10,R11,R12-phenyl)-1-(R13,R14,R

Combination of a substituted pyrazoline compound and a drug used in food-related disorders

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one compound used in food-related disorders, a medicament comprising said active substance combination, a pharmaceutical

Use of substituted pyrazoline compounds for the preparation of paediatric medicaments

The present invention relates to the use of substituted pyrazoline compounds for the manufacture of a medicament for prophylaxis and/or treatment of a food-related disorder in a paediatric patient, whereby said medicament is administered at a dosage of 0.

Combination of pyrazoline type cannabinoid receptor antagonist and statin

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one statin compound, a medicament comprising said active substance combination, a pharmaceutical formulation comprising s

Pharmaceutical formulations of substituted pyrazoline compounds

The present invention relates to the use of substituted pyrazoline compounds characterized in that the pharmaceutical formulation is in the form selected from: €￠ An oral osmotically driven system for the release of the compound €￠ A parenteral Implant €￠